Status:
UNKNOWN
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
University of Copenhagen
Conditions:
Vagotomy, Truncal
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion. The hypothesis is t...
Detailed Description
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 int...
Eligibility Criteria
Inclusion
- normal fasting plasma glucose
- normal hemoglobin
- informed consent
Exclusion
- type 1 diabetes mellitus or type 2 diabetes mellitus
- body mass index \> 30
- inflammatory bowel disease
- intestinal surgery
- serum creatinine \> 250 µM and/or albuminuria
- ALAT \> 2 x normal value
- Severe cardiac insufficiency
- in treatment with medicine which cannot be paused for 12 hours
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01176760
Start Date
August 1 2009
End Date
December 1 2012
Last Update
December 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of internal medicine F´laboratory, Gentofte Hospital
Hellerup, Copenhagen, Denmark, 2900